<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>volume-based drug procurement &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/volume-based-drug-procurement/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Oct 2026 17:44:37 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>volume-based drug procurement &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>China&#8217;s volume-based drug procurement linked to modest rise in R&#038;D intensity</title>
		<link>https://bioengineer.org/chinas-volume-based-drug-procurement-linked-to-modest-rise-in-rd-intensity/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 24 Oct 2026 17:44:37 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[A-share listed firms]]></category>
		<category><![CDATA[BMC Health Services Research]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cost containment]]></category>
		<category><![CDATA[difference-in-differences]]></category>
		<category><![CDATA[drug pricing]]></category>
		<category><![CDATA[Health Policy]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical innovation]]></category>
		<category><![CDATA[R&D intensity]]></category>
		<category><![CDATA[Volume-based]]></category>
		<category><![CDATA[volume-based drug procurement]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=452091</guid>

					<description><![CDATA[A study of 293 Chinese A-share listed pharmaceutical manufacturers finds direct selection in national volume-based drug procurement was associated with modestly higher R&#38;D intensity, though supplementary measures and specification checks temper causal interpretation.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">452091</post-id>	</item>
	</channel>
</rss>
